Recent Developments in Drug Design of NO-donor Hybrid Compounds

Author(s): Rajan Sharma, Jacques Joubert, Sarel F. Malan*

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 18 , Issue 14 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


The free radical nitric oxide (NO) is considered one of the most versatile endogenous molecules and is a crucial signalling molecule in numerous biochemistry pathways of the human body. NO is directly related to pathological processes and plays an important role in many different and interrelated physiological processes. In some cases, a depletion of NO or an attenuation of its effector system could exist as in hypertension, angina and impotence; in others, an overproduction of NO may be a major cause of damage, as in circulatory shock, sepsis, neurodegenerative disorders and inflammatory responses. By using certain functional groups present in molecules that already have potential therapeutic value, hybrid compounds, by means of inclusion of NO-donors (e.g., ester nitrates and nitrites, S-nitrosothiols, metal complexes, furoxans, oxadiazoles, diazeniumdiolates and NO nanoparticles), can be developed that have a NO release benefit along with maintaining the activity of the native drug. The objective of the design of NO-donor hybrid compounds is to achieve a balance between the release of therapeutic amounts of NO, especially in the site of action, and maintaining the native drug activity. This review explores some of the most promising recent advances in NO-donor drug development and addresses the challenges associated with NO as a therapeutic agent.

Keywords: Nitric Oxide, NO-donor, hybrid drug compounds, NO, immune defence, drug design.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 09 July, 2018
Page: [1175 - 1198]
Pages: 24
DOI: 10.2174/1389557518666180416150005
Price: $65

Article Metrics

PDF: 69